OCX NASDAQ
OncoCyte Corporation
1W: -6.3%
1M: +7.6%
3M: -2.1%
1Y: -6.0%
3Y: -83.9%
5Y: -88.6%
$3.20
Last traded 2025-07-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships0
As Filer
counterparties named
5
As Counterparty
mentioned by others
2022-01-18
Earliest Filing
2025-01-08
Latest Filing
Mentioned As Counterparty
5 mentionsOther companies that named OCX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| IMDX Oncocyte Corp | partner | Original tenant entering lease amendment and waiver | 2025-01-08 | View |
| IMDX Oncocyte Corp | partner | Partnered with Bio-Rad for global commercialization of GraftAssure assay | 2024-04-11 | View |
| IMDX Oncocyte Corp | acquirer | Seller of the purchased shares in the Stock Purchase Agreement. | 2023-02-23 | View |
| IMDX Oncocyte Corp | partner | Terminated collaboration agreement with Life Technologies Corporation | 2023-02-13 | View |
| IMDX Oncocyte Corp | partner | Announced a development and co-marketing agreement for IVD assays on Thermo Fisher Scientific's Genexus System. | 2022-01-18 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR